Top Markets
Coin of the day
Abivax S.A. Abivax S.A.

Abivax S.A.

ABVX
Rangering i aksjer #2071
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Aksjekurs
$121.34
Markedsverdi
$10.58B
Endring (1 dag)
4.28%
Endring (1 år)
59.66%
Land
FR
Handel Abivax S.A. (ABVX)

Kategori

Aksjeprishistorikk for Abivax S.A. (ABVX)
Høyeste sluttskurs: $124.98 den 2026-08-01

Laveste sluttskurs: $23.10 den 2015-06-01
Aksjeprishistorikk for Abivax S.A. fra 2015 til 2026
Årlig aksjeprisytelse
År Ytelse
2026 (TTM) -8.61%
2025 1,503.20%
2024 -26.43%
2023 60.28%
2022 -77.75%
2021 -2.30%
2020 54.91%
2019 56.94%
2018 22.67%
2017 47.19%
2016 -57.07%
2015 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$551.73 41.85%
US
$1.03K 51.89%
NL
$154.73 510.36%
US
$122.47 -12.71%
AU
$775.65 9.15%
CH